FDA adcomm votes against new indication for Genentech's cancer drug
The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US patient population for a Columvi label expansion. Genentech is seeking approval for Columvi (glofitamab) in ...
The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US patient population for a Columvi label expansion.
Genentech is seeking approval for Columvi (glofitamab) in ...
